Researchers shoot wing off HIV drug rationale
July 30th, 2006
HIV hides in guts, immune to expensive ARVs
Years of hideous side effects for nothing?
“I thought you would be interested to read this article from The Times”, writes a thoughtful correspondent, MG, and indeed the latest effort by Sam Lister, the health correspondent of the Times of London, seems worth noting.
According to his story yesterday (Sat Jul 29) HIV hides itself in the intestines to beat drugs, ARVs (antiretrovirals) are now shown to have no effect on HIV in the guts, where the nightmare virus establishes itself securely to attack the 70% of the immune system located there.
The scientists found that the virus that causes Aids took hold in intestinal tissue of patients receiving antiretroviral therapy (ARV). There it continued to replicate and suppress the immune system even though blood samples showed that the drugs were working.
Professor Satya Dandekar, who led the study, said that, while ARV could be quite successful in reducing HIV’s presence in the blood, the virus still thrived. “The real battle between the virus and exposed individuals is happening in the gut immediately after viral infection,” she said. “We need to be focusing our efforts on improving treatment of gut mucosa, where massive destruction of immune cells is occurring.”
Professor Dandekar, head of the university’s department of medical microbiology and immunology, said that gut-associated lymphoid tissue accounted for 70 per cent of the body’s immune system, and that restoring its function was crucial to destroying the virus.
So why take ARVs at all, then, if HIV can and will easily hide out in the guts and do its dirty work on 70% of the body’s immune system cells there?
That’s too simple, according to the study authors at Davis, whose research is supported by the NIH. They do not come to this obvious conclusion. On the contrary, their prescription is to start treatment earlier.
Thomas Prindiville, the study’s co-author, said that starting treatment earlier significantly improved the chances of restoring immune function.“If we are able to restore the gut’s immune response, the patient will be more likely to clear the virus,” Professor Prindiville said. “You can’t treat any infectious disease without the help of the immune system.”
How early is early? Judging from the monkey studies a year ago April that first suggested this line of thinking, because they found that simian immunodeficiency virus decimated immune cells in the guts of monkeys within days, early means patients should receive ARVs within a few days.
Those who keep up with the newsflow of this paradigm will recognize this as a contribution to the current campaign to expand testing to the entire population of the United States as soon as possible.
In fact, it takes us one step closer to justifying prophylactic medication for everyone “at risk” in the US. Except for one thing - the mysterious fact that this wholesale destruction within days of the 70% of our CD4 cells in our gut doesn’t seem to have any long term effect. Everything soon goes back to normal for as long as twenty or thirty years - however long the “latent” period is.
Granted that the report may be garbled but the item seems to show that there is no limit to how new findings can be twisted to serve the cause of what is no longer a scientifically based enterprise in any meaningful way.
The Times July 29, 2006
HIV hides itself in the intestines to beat drugs
By Sam Lister, Health Correspondent
HIV can avoid the powerful drugs that sufferers take to destroy it by hiding in their guts, scientists have discovered.
The scientists found that the virus that causes Aids took hold in intestinal tissue of patients receiving antiretroviral therapy (ARV). There it continued to replicate and suppress the immune system even though blood samples showed that the drugs were working.
The scientists from California University said that results of their three-year study, published in the Journal of Virology, showed HIV treatments needed re-evaluation.
Professor Satya Dandekar, who led the study, said that, while ARV could be quite successful in reducing HIV’s presence in the blood, the virus still thrived. “The real battle between the virus and exposed individuals is happening in the gut immediately after viral infection,” she said. “We need to be focusing our efforts on improving treatment of gut mucosa, where massive destruction of immune cells is occurring.”
Professor Dandekar, head of the university’s department of medical microbiology and immunology, said that gut-associated lymphoid tissue accounted for 70 per cent of the body’s immune system, and that restoring its function was crucial to destroying the virus.
The study suggests that earlier ARV and the use of anti-inflammatory drugs could achieve this. It also urges gut biopsies on all patients receiving ARV as a way of monitoring their condition.
“We found a substantial delay in the time that it takes to restore the gut mucosal immune system in those with chronic infections,” Professor Dandekar said. “In these patients the gut acted as a viral reservoir that keeps us from ridding patients of the virus.”
Doctors have long relied on measuring HIV’s presence in the blood and T-cell counts. T-cells, also called T-helper cells, organise the immune system’s fight against viruses. However, their numbers are reduced when HIV enters the body, leaving carriers vulnerable to infection.
Earlier research by Professor Dandekar and her team supports the claim that patients with high numbers of T-cells in their gut tissue were likely to live longer.
Thomas Prindiville, the study’s co-author, said that starting treatment earlier significantly improved the chances of restoring immune function.
“If we are able to restore the gut’s immune response, the patient will be more likely to clear the virus,” Professor Prindiville said. “You can’t treat any infectious disease without the help of the immune system.”
The scientists followed ten patients receiving highly active antiretroviral therapy, known as HAART. Three of the patients were treated within six weeks of finding out they were HIV positive.
(hide)
Here’s a more informed report from RxPG News:
RxPG News
Jul 30th, 2006 - 02:34:25
HIV hides from drugs in gut, preventing immune recovery
Jul 30, 2006, 02:32, Reviewed by: Dr. Priya Saxena
“This is the first longitudinal study to show that, while current HIV therapy is quite successful in reducing viral loads and increasing T-cells in peripheral blood, it is not so effective in gut mucosa”
By University of California, Davis, UC Davis researchers have discovered that the human immunodeficiency virus, the virus that causes AIDS, is able to survive efforts to destroy it by hiding out in the mucosal tissues of the intestine. They also found that HIV continues to replicate in the gut mucosa, suppressing immune function in patients being treated with antiretroviral therapy–even when blood samples from the same individuals indicated the treatment was working.
“This is the first longitudinal study to show that, while current HIV therapy is quite successful in reducing viral loads and increasing T-cells in peripheral blood, it is not so effective in gut mucosa,” said Satya Dandekar, professor and chair of the Department of Medical Microbiology and Immunology at UC Davis Health System and senior author of the study.
“The real battle between the virus and exposed individuals is happening in the gut immediately after viral infection,” she said. “We need to be focusing our efforts on improving treatment of gut mucosa, where massive destruction of immune cells is occurring. Gut-associated lymphoid tissue accounts for 70 percent of the body’s immune system. Restoring its function is crucial to ridding the body of the virus.”
Results of the study suggest that patients being treated with antiretroviral therapy should be monitored using gut biopsies and that the gut’s immune function be restored through earlier antiretroviral treatment and the use of anti-inflammatory medications.
“We found a substantial delay in the time that it takes to restore the gut mucosal immune system in those with chronic infections,” Dandekar said. “In these patients the gut is acting as a viral reservoir that keeps us from ridding patients of the virus.”
Physicians treating HIV-infected patients have long relied on blood measurements of viral load and T-cell counts when choosing a course of treatment. Viral load is the number of viral particles in a milliliter sample of blood. T-cell counts reflect the number of CD4+ T-cells in the sample. These cells, also called T-helper cells, organize the immune system’s attack on disease-causing invaders. They are, however, the targets of the virus and their numbers decrease as the amount of HIV increases, leaving the body vulnerable to a variety of infections.
Last year, Dandekar’s team published a study of HIV-infected patients who, despite the lack of treatment, had survived over 10 years with healthy levels of T-cells and suppressed viral loads.
“We looked at their gut lymphoid tissue and did not see loss of T-cells there. This correlated with better clinical outcomes,” Dandekar explained.
Those results prompted Dandekar and her team to undertake the current study in which they set out to evaluate the effect of highly active antiretroviral therapy, known as HAART, on viral suppression and immune restoration in gut-associated lymphoid tissue. They followed 10 patients being treated with HAART, taking blood and gut samples before and after three years of treatment. Three of the patients were treated during four to six weeks of first being infected with the virus. The other participants were known to be HIV positive for more than one year.
Hoping to figure out why HAART does not work as well in the gut, Dandekar and her colleagues further examined the post-treatment of gut-associated lymphoid tissue samples. They found evidence of inflammation, which disrupts tissue function, promotes cell death and upsets the normal balance of gut flora. They also found that the activity of genes that control and promote mucosal repair and regeneration were suppressed, while the genes responsible for the inflammatory response were more active than in normal tissue.
Dandekar said these results suggest anti-inflammatory drugs may improve antiretroviral treatment outcomes. She also pointed out that genes involved with the repair and regeneration of gut-associated lymphoid tissue would make excellent drug targets.
Researchers then compared HAART outcomes in those who chose to be treated within the weeks of exposure to those with chronic infection. They discovered that newly infected patients had fewer signs of inflammation at the beginning of the study and experienced greater recovery of the gut mucosal immune system function by the end of it.
Dandekar and her colleagues are currently following additional patients being treated with HAART. Unpublished data on these patients supports the current findings, said Thomas Prindiville, a gastroenterology professor at UC Davis and a co-author of the study.
“What we continue to see is that restoration of immune function is more likely when treatment is started early,” said Prindiville. “Starting HAART before T-cell counts fall below 350 cells per cubic milliliter, would preserve immune function and hasten its full recovery.”
The team of physicians and researchers plan to keep testing ways of improving the efficacy of antiretroviral therapy in gut-associated lymphoid tissue. These include treating gut inflammation, starting treatment earlier and using gut biopsies to monitor treatment success.
“If we are able to restore the gut’s immune response, the patient will be more likely to clear the virus,” Prindiville said. “You can’t treat any infectious disease without the help of the immune system.”
- Results of the three-year study appear in the August issue of the Journal of Virology
jvi.asm.org
(hide)
Professor Satya Dandekar, who led the study, said that, while ARV could be quite successful in reducing HIV’s presence in the blood, the virus still thrived. “The real battle between the virus and exposed individuals is happening in the gut immediately after viral infection,” she said. “We need to be focusing our efforts on improving treatment of gut mucosa, where massive destruction of immune cells is occurring.”
Tucked away on page 26 of the Times today, this AP report: 
Now Harvey Bialy has routed John Moore on Amazon, with Moore forced by Amazon to replace his childishly dismissive review of Bialy’s exemplary book, “Aneuploidy, Oncogenes and AIDS: A Scientific Life and Times of Peter H. Duesberg”, with a rewrite (it was against the rules to include the referral to his misleading 
Meanwhile, today we have yet another positive review from a respected source,
Honestly, could one ask for a simpler, more truthful sounding recommendation? Exhibit B, Dr. Moore! Readers can compare all these with